TherapeuticsMD Inc

NASDAQ:TXMD   11:52:30 AM EDT
1.24
+0.04 (+2.92%)
Products

Therapeuticsmd Announces Submission Of Low Dose Bijuva® 0.5 Mg/100 Mg Supplemental New Drug Application To FDA

Published: 05/25/2021 11:19 GMT
TherapeuticsMD Inc (TXMD) - Therapeuticsmd Announces Submission of Low Dose Bijuva® 0.5 Mg/100 Mg Supplemental New Drug Application to FDA.
Therapeuticsmd - Expects to Learn of Acceptance of Snda Upon Receipt of Filing Review Notification From FDA, Approximately 74 Days After Submission.
Therapeuticsmd Inc - Expects Review Time Under PDUFA Will Be Within Ten Months of Receipt by FDA, Approximately March 21, 2022.